Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Toxicity in NOD/SCID mouse xenografted with human LY2298 tumor harboring Myd88-L265P and CD79B mutant assessed as body weight change at 100 mg/kg,po QD measured after 6 hrs in presence of venetoclax
Assay data:1 Tested
SummaryPubMed Citation
Toxicity in NOD/SCID mouse xenografted with human LY2298 tumor harboring Myd88-L265P and CD79B mutant assessed as body weight change at 100 mg/kg,po QD measured after 6 hrs
Antitumor activity against human B-lymphocytes harboring Myd88-L265P and CD79B mutant from LY2298 tumor xenografted NOD/SCID mouse model assessed as tumor growth inhibition at 100 mg/kg,po QD measured after 6 hrs in presence of venetoclax
Antitumor activity against human B-lymphocytes harboring Myd88-L265P and CD79B mutant from LY2298 tumor xenografted NOD/SCID mouse model assessed as tumor growth inhibition at 100 mg/kg,po QD measured after 6 hrs
Toxicity in NSG mouse xenografted with human OCI-Ly10 cells assessed as body weight change at 5 to 50 mg/kg, po BID for 3 weeks
Toxicity in NSG mouse xenografted with human OCI-Ly10 cells assessed as body weight change at 10 to 100 mg/kg, po QD for 3 weeks
Antitumor activity against human OCI-Ly10 cells xenografted in NSG mouse assessed tumor growth inhibition at 50 mg/kg,po BID for 3 weeks
Antitumor activity against human OCI-Ly10 cells xenografted in NSG mouse assessed tumor growth inhibition at 15 mg/kg, BID for 3 weeks
Antitumor activity against human OCI-Ly10 cells xenografted in NSG mouse assessed tumor growth inhibition at 5 mg/kg, BID for 3 weeks
Antitumor activity against human OCI-Ly10 cells xenografted in NSG mouse assessed tumor growth inhibition at 100 mg/kg, QD for 3 weeks
Antitumor activity against human OCI-Ly10 cells xenografted in NSG mouse assessed tumor growth inhibition at 30 mg/kg, QD for 3 weeks
Antitumor activity against human OCI-Ly10 cells xenografted in NSG mouse assessed tumor growth inhibition at 10 mg/kg, QD for 3 weeks
Antitumor activity against human OCI-Ly10 cells xenografted in NSG mouse assessed tumor growth inhibition at 50 mg/kg, BID for 3 weeks relative to control
Antitumor activity against human OCI-Ly10 cells xenografted in NSG mouse assessed tumor growth inhibition at 10 mg/kg, BID for 3 weeks relative to control
Antitumor activity against human OCI-Ly10 cells xenografted in NSG mouse assessed tumor growth inhibition at 5 mg/kg, BID for 3 weeks relative to control
Antitumor activity against human OCI-Ly10 cells xenografted in NSG mouse assessed tumor growth inhibition at 100 mg/kg, QD for 3 weeks relative to control
Antitumor activity against human OCI-Ly10 cells xenografted in NSG mouse assessed tumor growth inhibition at 30 mg/kg, QD for 3 weeks relative to control
Antitumor activity against human OCI-Ly10 cells xenografted in NSG mouse assessed tumor growth inhibition at 10 mg/kg, QD for 3 weeks relative to control
Invivo receptor occupancy at BTK in NSG mouse xenografted with human OCI-Ly10 cells assessed as free BTK level at 100 mg/kg, po and measured after 24 hrs by ELISA
Invivo receptor occupancy at BTK in NSG mouse xenografted with human OCI-Ly10 cells assessed as free BTK level at 30 mg/kg, po and measured after 24 hrs by ELISA
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on